https://www.octapharmausa.com/news/corporate-news/2025/our-approach-to-sustainability https://www.octapharmausa.com/news/patient-stories/2025/a-journey-of-patience-and-resilience https://www.octapharmausa.com/news/corporate-news/2025/setting-new-standards-in-patient-bleeding-management https://www.octapharmausa.com/news/donor-stories/2025/be-a-hero-time-and-time-again https://www.octapharmausa.com/career/join-our-team/job-detail/chargeback-analyst https://www.octapharmausa.com/news/corporate-news/2024/financial-review-2023 https://www.octapharmausa.com/career/join-our-team/job-detail/it-engineer-network-and-security https://www.octapharmausa.com/news/donor-stories/2025/from-survivor-to-advocate https://www.octapharmausa.com/news/donor-stories/2024/loyalty-and-community https://www.octapharmausa.com/news/corporate-news/2024/building-on-our-successes https://www.octapharmausa.com/career/join-our-team/job-detail/data-quality-analyst https://www.octapharmausa.com/news/corporate-news/2025/we-are-all-part-of-a-vital-chain https://www.octapharmausa.com/news/donor-stories/2024/just-an-ordinary-lifesaver https://www.octapharmausa.com/news/corporate-news/2019/celebrating-our-milestones https://www.octapharmausa.com/career/join-our-team/job-detail/key-account-manager-hospital-accounts-central-florida https://www.octapharmausa.com/news/corporate-news/2026/financial-review-2025 https://www.octapharmausa.com/news/corporate-news/2025/small-antibodies-with-big-implications https://www.octapharmausa.com/news/press-release/2021/fda-approves-octapharmas-cutaquig-for-pediatric-pi-patients-providing-flexible-treatment-options https://www.octapharmausa.com/news/press-release/2020/octapharma-usa-presents-research-on-congenital-acquired-bleeding-disorders-at-ash-annual-meeting https://www.octapharmausa.com/news/press-release/2020/octapharma-usa-presents-results-investigational-use-of-octagam10-for-severe-covid19-patients-at-ash-annual-meeting https://www.octapharmausa.com/news/press-release/2020/octapharma-announces-fda-approval-of-updated-nuwiq-prescribing-information-to-include-immunogenicity-data-in-previously-untreated-patients https://www.octapharmausa.com/news/press-release/2020/national-hemophilia-foundation-revises-treatment-guidelines-for-factor-1-deficiency-to-include-octapharmas-fibryga https://www.octapharmausa.com/news/press-release/2020/octapharma-usa-announces-medicare-part-b-approval-of-cutaquig-for-adult-pi-patients https://www.octapharmausa.com/news/press-release/2020/ivig-reduces-respiratory-morbidity-covid19-study-supported-octapharma https://www.octapharmausa.com/news/press-release/2020/octapharma-launches-phase-3-superiority-study-for-pediatric-acuteonset-neuropsychiatric-syndrome https://www.octapharmausa.com/news/press-release/2020/octapharma-takes-action-on-covid-19 https://www.octapharmausa.com/news/corporate-news/2026/octapharma-shareholders-look-back-on-2025-performance https://www.octapharmausa.com/news/patient-stories/2025/i-m-proud-of-who-i-ve-become https://www.octapharmausa.com/career/join-our-team/job-detail/key-account-manager-hospital-accounts-tennessee https://www.octapharmausa.com/news/corporate-news/2024/ops-tansforming-production-to-meet-rising-demand https://www.octapharmausa.com/news/press-release/2020/octapharma-usa-extends-funding-for-covid-19-study https://www.octapharmausa.com/news/corporate-news/2019/octapharma-group-reports-strong-results-for-2018 https://www.octapharmausa.com/news/our-employees/2025/employee-sara-lawson https://www.octapharmausa.com/news/press-release/2020/fda-approves-octapharma-usa-investigational-new-drug-application https://www.octapharmausa.com/news/corporate-news/2020/octapharma-statement-on-social-justice https://www.octapharmausa.com/news/innovation-and-science/2020/trust-swift-decision-making-and-excellent-medical-skills-are-a-priority-for-intensive-care https://www.octapharmausa.com/news/corporate-news/2019/new-data-on-haemophilia-a-or-von-willebrand-disease-at-isth-2019 https://www.octapharmausa.com/career/join-our-team/job-detail/key-account-manager-hospital-accounts-virginia https://www.octapharmausa.com/news/press-release/2025/octapharma-releases-results-phase3-superiority-study-pediatric-acuteonset-neuropsychiatric-syndrome https://www.octapharmausa.com/news/corporate-news/2025/how-big-data-is-changing-the-game-at-octapharma https://www.octapharmausa.com/news/innovation-and-science/2024/wil-31-expanding-treatment-options-for-vwd https://www.octapharmausa.com/news/corporate-news/2024/building-the-organization-of-tomorrow https://www.octapharmausa.com/news/patient-stories/2024/a-recipe-for-a-good-life https://www.octapharmausa.com/news/press-release/2020/isth2020-results https://www.octapharmausa.com/news/corporate-news/2020/continuing-to-invest-in-the-future-prosperity-of-octapharma https://www.octapharmausa.com/news/corporate-news/2018/octapharma-to-build-new-multi-use-venue https://www.octapharmausa.com/news https://www.octapharmausa.com/news/corporate-news/2019/update-on-the-development-of-subq-8-isth-2019 https://www.octapharmausa.com/career/join-our-team/job-detail/sap-support-specialist https://www.octapharmausa.com/news/press-release/2026/fda-approves-new-2-gram-presentation-of-fibryga https://www.octapharmausa.com/news/our-employees/2025/employee-caitlin-greff https://www.octapharmausa.com/news/corporate-news/2025/financial-review-2024 https://www.octapharmausa.com/news/innovation-and-science/2024/enabling-innovation-in-bleeding-management-and-critical-care https://www.octapharmausa.com/news/patient-stories/2024/access-for-everyone-learning-to-live-with-haemophilia https://www.octapharmausa.com/news/corporate-news/2023/it-started-with-a-belief https://www.octapharmausa.com/news/corporate-news/2023/octapharma-group-delivers-strong-growth-in-sales-and-operating-income-in-2022 https://www.octapharmausa.com/news/corporate-news/2020/continuing-the-impact-of-our-products-for-generations-to-come https://www.octapharmausa.com/news/innovation-and-science/2020/testing-boundaries https://www.octapharmausa.com/news/press-release/2020/octapharma-group-delivered-strong-growth-in-both-sales-and-operating-income-in-2019 https://www.octapharmausa.com/plasma https://www.octapharmausa.com/ https://www.octapharmausa.com/career/join-our-team/job-detail/key-account-manager-dc-de-md https://www.octapharmausa.com/news/press-release/2025/octapharma-usa-jama-publishes-results-investigational-four-factor-prothrombin-complex-concentrate-cardiac-surgical-bleeding https://www.octapharmausa.com/news/corporate-news/2025/built-on-strength-and-resilience https://www.octapharmausa.com/news/press-release/2024/octapharma-usa-receives-fda-emergency-use-authorization-for-octaplaslg-powder-allows-us-military-medical-providers-emergent-use-in-treatment-of-hemorrhage-or-coagulopathy https://www.octapharmausa.com/news/press-release/2024/octapharma-usa-jama-network-open-publishes-study-results-demonstrating-efficacy-safety-of-balfaxar-for-warfarin-reversal-in-urgent-surgery-invasive-procedures https://www.octapharmausa.com/news/press-release/2023/octapharma-usa-fda-grants-expanded-approval-to-wilate-as-the-first-vwf-concentrate-for-prophylaxis-in-all-types-of-vwd https://www.octapharmausa.com/news/press-release/2023/octapharma-usa-presents-factor-concentrates-for-perioperative-bleeding-symposium-for-asa-annual-meeting-attendees https://www.octapharmausa.com/news/press-release/2023/heroes-in-the-fight-octapharma-honored-myositis-research-at-tma-annual-patient-conference https://www.octapharmausa.com/news/press-release/2023/octapharmas-prothrombin-complex-concentrate-balfaxar-receives-fda-approval-for-warfarin-reversal-in-urgent-surgery-invasive-procedures https://www.octapharmausa.com/news/press-release/2023/journal-of-clinical-immunology-publishes-octapharma-usa-research-on-cutaquig-evaluating-pi-treatment-options https://www.octapharmausa.com/news/press-release/2023/octapharma-usa-grant-supports-pans-pandas-education-event-at-nhia-conference https://www.octapharmausa.com/news/press-release/2023/octapharma-usa-research-at-aaaai-cutaquig-study-at-higher-infusion-rates-presented https://www.octapharmausa.com/news/press-release/2023/octapharma-usa-requests-fda-approval-for-wilate-vwd-prophylaxis-supplement https://www.octapharmausa.com/news/press-release/2022/proderm-study-results-of-octagam-10-treatment-in-patients-with-dermatomyositis-published-in-the-new-england-journal-of-medicine https://www.octapharmausa.com/news/press-release/2022/as-omicron-spreads-nationally-octapharmas-fibryga-octaplas-become-increasingly-important-replacement-therapies https://www.octapharmausa.com/news/press-release/2021/fda-orphan-drug-approval-octapharmas-octagam-10percent-receives-7years-of-market-exclusivity-for-adult-dermatomyositis https://www.octapharmausa.com/news/press-release/2021/fda-approves-octapharmas-octagam10percent-for-adult-dermatomyositis https://www.octapharmausa.com/news/patient-stories/2021/adapting-to-change-whd-2021 https://www.octapharmausa.com/news/press-release/2021/fda-approvals-strengthen-octapharma-usa-pediatric-critical-care-product-portfolio https://www.octapharmausa.com/news/our-employees/2020/employee-martina-willis-mccullough https://www.octapharmausa.com/career/join-our-team https://www.octapharmausa.com/career/working-for-octapharma-usa https://www.octapharmausa.com/octapharma/ca-statements/ca-compliance-law https://www.octapharmausa.com/career https://www.octapharmausa.com/news/press-release/2017/octapharma-donates-30-5-million-international-units-of-its-medicine https://www.octapharmausa.com/news/patient-stories/2019/real-hope-for-brandon https://www.octapharmausa.com/news/our-employees/2019/an-eye-for-detail https://www.octapharmausa.com/news/our-employees/2018/research-that-helps-people https://www.octapharmausa.com/news/press-release/2018/new-canadian-study-to-improve-eradication-of-inhibitors https://www.octapharmausa.com/news/press-release/2019/octapharma-demonstrates-commitment-to-improving-haemophilia-a-treatment-at-eahad https://www.octapharmausa.com/about-us/who-we-are https://www.octapharmausa.com/about-us/diseases-and-therapies https://www.octapharmausa.com/about-us https://www.octapharmausa.com/engagement/events https://www.octapharmausa.com/engagement https://www.octapharmausa.com/products/product-overview https://www.octapharmausa.com/products https://www.octapharmausa.com/news/press-release/2024/fda-approves-additional-indication-for-fibryga-for-fibrinogen-supplementation-in-bleeding-patients-with-acquired-fibrinogen-deficiency https://www.octapharmausa.com/news/our-employees/2023/employee-camille-hibbert https://www.octapharmausa.com/about-us/diseases-and-therapies/hematology-portfolio https://www.octapharmausa.com/octapharma/pharmacovigilance-data-privacy-statement https://www.octapharmausa.com/octapharma/ca-statements/comprehensive-compliance-program https://www.octapharmausa.com/news/press-release/2017/octapharma-usa-grant-supports-mission-of-first-hemophiliac-to-climb-the-seven-summits-of-the-world https://www.octapharmausa.com/news/patient-stories/2020/always-on-the-go https://www.octapharmausa.com/news/patient-stories/2019/engaging-with-patients https://www.octapharmausa.com/news/our-employees/2018/saving-lives https://www.octapharmausa.com/news/our-employees/2019/getting-our-medicines-to-patients https://www.octapharmausa.com/news/press-release/2018/octapharma-receives-swissmedic-approval-for-fibryga https://www.octapharmausa.com/news/press-release/2019/positive-results-for-fibryga-published-in-the-journal-of-thrombosis-and-haemostasis https://www.octapharmausa.com/about-us/who-we-are/leadership https://www.octapharmausa.com/about-us/diseases-and-therapies/hematology https://www.octapharmausa.com/engagement/patient-engagements https://www.octapharmausa.com/products/product-overview/octagam https://www.octapharmausa.com/news/press-release/2024/octapharma-usa-fda-grants-orphan-drug-exclusivity-to-wilate-the-first-vwf-concentrate-for-prophylaxis-in-all-types-of-vwd https://www.octapharmausa.com/octapharma/transparency-in-coverage https://www.octapharmausa.com/career/working-for-octapharma-usa/culture https://www.octapharmausa.com/career/join-our-team/job-openings https://www.octapharmausa.com/octapharma/ca-required-statements https://www.octapharmausa.com/octapharma/ca-statements/ca-privacy-statement https://www.octapharmausa.com/products/product-overview/octaplas https://www.octapharmausa.com/news/press-release/2017/octapharma-usa-sponsors-nhf-annual-meeting https://www.octapharmausa.com/news/our-employees/2019/using-big-data-to-improve-lives https://www.octapharmausa.com/news/our-employees/2018/ensuring-safety-and-suitability-of-donors https://www.octapharmausa.com/news/press-release/2018/octapharma-announces-approval-of-new-nuwiq-product-strengths https://www.octapharmausa.com/news/press-release/2019/final-results-from-the-nuprotect-study-demonstrating-efficacy-of-nuwiq https://www.octapharmausa.com/about-us/who-we-are/milestones https://www.octapharmausa.com/about-us/diseases-and-therapies/immunotherapy https://www.octapharmausa.com/products/production-process https://www.octapharmausa.com/career/join-our-team/job-detail/key-account-manager-south-ca-south-nv https://www.octapharmausa.com/news/press-release/2024/publication-of-data-from-wil-31-study-marks-a-milestone-in-improving-long-term-care-for-patients-with-severe-von-willebrand-disease-vwd https://www.octapharmausa.com/products/product-overview/balfaxar https://www.octapharmausa.com/about-us/who-we-are/compliance-program https://www.octapharmausa.com/career/working-for-octapharma-usa/employee-benefits https://www.octapharmausa.com/products/product-overview/albumin https://www.octapharmausa.com/octapharma/terms-of-use https://www.octapharmausa.com/news/press-release/2017/octapharma-usa-sponsors-hope-ignites-stories-to-inspire https://www.octapharmausa.com/news/patient-stories/2020/surviving-the-unknown https://www.octapharmausa.com/news/innovation-and-science/2017/blood-is-essential-for-the-wellbeing-of-everyone https://www.octapharmausa.com/news/our-employees/2019/controlling-the-plasma https://www.octapharmausa.com/news/our-employees/2018/detecting-viruses-early https://www.octapharmausa.com/news/press-release/2018/octapharma-present-new-data-on-the-benefits-of-nuwiq https://www.octapharmausa.com/news/press-release/2019/final-results-from-the-nuprotect-study https://www.octapharmausa.com/about-us/diseases-and-therapies/critical-care https://www.octapharmausa.com/about-us/research-and-development https://www.octapharmausa.com/products/quality-and-safety https://www.octapharmausa.com/news/press-release/2024/octapharma-announces-availability-of-balfaxar-for-warfarin-reversal-in-urgent-surgery-invasive-procedures https://www.octapharmausa.com/products/industrial-collaboration https://www.octapharmausa.com/news/our-employees/2020/employee-kevin-uskovich https://www.octapharmausa.com/octapharma/privacy-statement https://www.octapharmausa.com/news/our-employees/2019/medicine-as-an-art-form https://www.octapharmausa.com/news/our-employees/2018/performing-analytical-methods https://www.octapharmausa.com/news/press-release/2017/publication-of-clinical-data-demonstrating-low-immunogenicity-and-excellent-efficacy-of-nuwiq https://www.octapharmausa.com/news/press-release/2018/low-inhibitor-rate-with-octanate-in-previously-untreated-patients https://www.octapharmausa.com/news/press-release/2019/fibryga-receives-european-label-extension-to-treat-acquired-fibrinogen-deficiency-afd https://www.octapharmausa.com/about-us/our-locations https://www.octapharmausa.com/products/product-overview/cutaquig https://www.octapharmausa.com/career/join-our-team/job-detail/coordinator-speaker-events https://www.octapharmausa.com/products/industrial-customers-contact https://www.octapharmausa.com/news/our-employees/2020/employee-mike-bland https://www.octapharmausa.com/news/press-release/2018/octapharma-share-promising-preclinical-data-for-subq-8 https://www.octapharmausa.com/news/our-employees/2018/documenting-the-complete-history-of-every-production-batch https://www.octapharmausa.com/news/press-release/2017/octapharma-underlines-strong-commitment-to-haemophilia-a-patients https://www.octapharmausa.com/news/press-release/2019/octapharma-announces-publication-of-data-on-fibryga https://www.octapharmausa.com/products/product-overview/fibryga https://www.octapharmausa.com/news/press-release/2019/octapharma-group-reports-strong-results-for-2018 https://www.octapharmausa.com/news/press-release/2018/octapharma-group-publishes-2017-annual-results https://www.octapharmausa.com/news/our-employees/2019/from-childhood-dream-to-research-team https://www.octapharmausa.com/news/our-employees/2018/around-the-clock-production https://www.octapharmausa.com/news/press-release/2017/isth-2017-berlin-octapharma-presents-exciting-nuwiq-data https://www.octapharmausa.com/products/product-overview/nuwiq https://www.octapharmausa.com/news/our-employees/2020/employee-snehal-udavat https://www.octapharmausa.com/news/press-release/2017/octapharma-symposium-at-isth-berlin https://www.octapharmausa.com/news/press-release/2019/new-data-isth-2019 https://www.octapharmausa.com/news/our-employees/2018/maintaining-the-cold-chain https://www.octapharmausa.com/products/product-overview/panzyga https://www.octapharmausa.com/career/join-our-team/job-detail/patient-experience-manager-md-wv-va-nc-de-dc-sc https://www.octapharmausa.com/about-us/contact-us https://www.octapharmausa.com/news/press-release/2017/octapharma-activities-prominent-at-the-upcoming-2017-isth-congress https://www.octapharmausa.com/news/press-release/2019/update-on-the-development-of-subq-8-isth-2019 https://www.octapharmausa.com/news/our-employees/2018/separating-plasma-proteins https://www.octapharmausa.com/products/product-overview/wilate https://www.octapharmausa.com/about-us/medical-affairs https://www.octapharmausa.com/news/our-employees/2020/employee-syed-rizvi https://www.octapharmausa.com/news/press-release/2017/octapharma-group-publishes-2016-annual-results https://www.octapharmausa.com/news/press-release/2019/new-data-on-haemophilia-a-or-von-willebrand-disease-at-isth-2019 https://www.octapharmausa.com/news/our-employees/2018/getting-the-right-material https://www.octapharmausa.com/news/press-release/2019/update-of-summary-of-product-characteristics-for-nuwiq https://www.octapharmausa.com/news/our-employees/2018/validating-cleaning-methods https://www.octapharmausa.com/news/our-employees/2018/cultivating-factor-viii https://www.octapharmausa.com/news/our-employees/2020/adam-llarena-single-donation-controller https://www.octapharmausa.com/news/our-employees/2018/purifying-products https://www.octapharmausa.com/news/our-employees/2020/we-are-octapharma https://www.octapharmausa.com/news/our-employees/2018/investing-to-increase-capacity-and-automation https://www.octapharmausa.com/news/our-employees/2018/preserving-human-proteins https://www.octapharmausa.com/news/our-employees/2018/bringing-new-optimal-therapies https://www.octapharmausa.com/news/our-employees/2018/timely-help-for-critically-ill-patients